Patent number: 5585382
Abstract: Anticancer compounds of formula I: ##STR1## and pharmaceutically acceptable salts thereof, wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.10 are independently selected from the group H, C.sub.1 -C.sub.4 alkyl, OR.sup.4, N(R.sup.4).sub.2, NO.sub.2, CN, F, Cl, Br, I, Ph, and CF.sub.3, and NHC(O)R.sup.4 ;R.sup.4 is independently selected from the group H, C.sub.1 -C.sub.4 alkyl, Ph, and CH.sub.2 Ph;X.sup.1 and Y.sup.1, and X.sup.2 and Y.sup.2 when present, join together to form:a benzene ring substituted with 1-4 R.sup.3 ;a five membered heterocycle having 1-2N, NH, O or S atoms and substituted with 1-2 R.sup.3 ;a six membered heterocycle having 1-2N and substituted with 1-2 R.sup.3 ; orthe group: ##STR2## wherein one of W or Z is C.dbd.O and the other is C.dbd.O, NH, S or O; or when X.sup.2 and Y.sup.2 are present and not joined together and when R.sup.2 is in the 4-position, then X.sup.2 and R.sup.2 may join together to form an ethylene bridge;are addressed.
Type:
Grant
Filed:
February 21, 1995
Date of Patent:
December 17, 1996
Assignee:
The DuPont Merck Pharmaceutical Company
Inventors:
Arthur D. Patten, Gregory Pacofsky, Steven P. Seitz, Emeka A. Akamike, Robert J. Cherney, Robert F. Kaltenbach, III, Michael J. Orwat